Taris Biomedical has completed Phase 1 clinical study of its intravesical drug-device convergence system designed to provide sustained-release of drug directly to the bladder. The study was designed to evaluate the safety, tolerability and retention of the Taris drug-device convergence system in the bladder.

Taris has developed a lidocaine-releasing intravesical system (LiRIS) that supplies a sustained release of lidocaine directly to the bladder. Lidocaine has been shown in scientific literature and clinical practice, to decrease symptoms associated with bladder diseases, such as bladder pain and urgency when instilled directly into the bladder.

The Taris core platform technology, which was developed by MIT, enables local sustained delivery of drug directly to the target tissue through drug-device convergence.

Christine Bunt, co-founder and COO of Taris Biomedical, said: “In just one year we have rapidly advanced this technology from in-licensing through Phase 1 human clinical testing. This Phase 1 study successfully establishes proof-of-concept for the Taris sustained-release technology and positions us for mid-stage clinical development with our LiRIS (Lidocaine Releasing Intravesical System) in interstitial cystitis (IC), our first indication, in 2010.”

Robert Langer, professor of David Koch Institute at the Massachusetts Institute of Technology and co-founder of Taris Biomedical, said: “The success of this early study is a significant milestone for Taris. It validates the core platform technology and opens up the potential of this drug-device convergence system, beyond IC, into a variety of bladder diseases such as bladder cancer and overactive bladder.”